Mitoxantrone in secondarily progressive multiple sclerosis: A series of 18 patients

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 2, 2005, Pages 225-227

  Montú, María Belén ^a,c   Arruda, Walter Oleschko ^a,b   De Oliveira, Marcelo De Souza R ^a   Ramina, Ricardo ^a  

^a INSTITUTO DE NEUROLOGIA DE CURITIBA   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Neurology   (Brazil)

Author keywords

Demyelinating disease; Mitoxantrone; Multiple sclerosis

Indexed keywords

MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AMENORRHEA; CARDIOTOXICITY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; RELAPSE; REMISSION; REVIEW;

EID: 20644440217     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2005000200007     Document Type: Review

References (22)

1. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
2. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the therapeutics and techonology assessment subcomittee of the American Academy of Neurology. Neurology 2003;61:1332-1338.
3. Kohriyama T, Higaki M, Matsumoto M, Newer disease-modifying drugs: glatiramer acetate and mitoxantrone. Nippon Rinsho 2003;61:1381-1387.
4. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 2003;206:203-208.
5. Ozawa K. Immunologic therapy for secondary and primary progressive multiple sclerosis. Nippon Rinsho 2003;61:1449-1454.
6. Murray TJ. Mitoxantrone slowed progression of disability and reduced relapses in multiple sclerosis. ACP J Club 2003;139:145.
7. Polman CH, Uitdehaag BM. New and emerging treatment options for multiple slcerosis. Lancet Neurol 2003;2:563-566.
8. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2203;23:133-146.
9. Kieseier BC, Hartung HP. Multiple paradigm shifts in multiple sclerosis. Curr Opin Neurol 2003;16:247-252.
10. Gonsette RE. Mitoxantrone in progressive multiple scleorsis: when and how to treat? J Neurol Sci 2003;206:203-208.
11. Drug helps delay progression of multiple sclerosis. FDA Consum 2001;35:4.
12. Edan G. Treatment of progressive forms of multiple sclerosis. Rev Neurol (Paris) 2001;157:1008-1013.
13. Noseworthy JH, Management of multiple sclerosis: current trials and future options. Curr Opin Neurol 2003;16:289-297.
14. Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C. Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003;49:137-141.
15. Corboy JR, Goodin DS, Frohman EM. Disease-modifying therapies for multiple sclerosis. Curr Treat Options Neurol 2003;5:35-54.
16. Millefiorini E, Gasperini C, Pozzilli C. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
17. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
18. Bastianello S, Pozzilli C, D'Andrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21:266-270.
19. Pericot I, Montalban X. Mitoxantrone. Neurologia 2003;18:318-323.
20. Myers LW. Immunologic therapy for secondary and primary progressive multiple sclerosis. Curr Neurol Neurosci Rep 2001;1:286-293.
21. http://www.nationalmssociety.org/pdf/research/agents.pdf. Accessed in July 19, 2004.
22. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and Interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther 2003;25:611-634.